BiotechTube
Home/Atrium Therapeutics/Kath Gallagher
KG

Kath Gallagher

Chief Executive Officer

Atrium Therapeutics

Therapeutic Areas

CardiovascularRare Disease

Atrium Therapeutics Pipeline

DrugIndicationPhase
ATR 1072PRKAG2 SyndromePre-clinical
ATR 1086PLN CardiomyopathyPre-clinical